Community Access National Network Releases Policy Report on 340 Drug Pricing Program

A Patient's Guide to 340B: Why the Program Matters to You

News provided by

Oct 19, 2021, 10:07 ET

WASHINGTON, Oct. 19, 2021 /PRNewswire/ -- In 1992, Congress struck a deal with pharmaceutical manufacturers to expand access to care and medication for more patients: If pharmaceutical manufacturers wanted to be included in Medicaid's coverage, they'd have to offer their products to outpatient entities serving low-income patients at a discount. The idea was brilliantly simple; drug manufacturers could have a guaranteed income from participation in the Medicaid program, and "covered entities" could have guaranteed access to discounted medications. Congress set-up a payment system by way of rebates, affording healthcare providers a way to fund much-needed care to patients who could not otherwise afford it.